and Thank everyone. hello you, Jed
in happy today's and I'm the to with always, As you provide participate side. call updates from clinical
I'll our the in Xb Phase So with progress begin RA. on trial NAVX-XX
in on in analysis of the I occurred months set and announced of midst we patients close the the the all in have full As call study, ago, all two this are out. and data visits trial
forward to trial have we and RA. data you from far moving it in this us As analyzed thus the were know, critical
the Phase both As the a we active tilmanocept arm arm, X is with repeatability, subjects three imaging in a patients In trial. data stability sizing in one third readout we efficacy. with in for to and Phase of reminder, of predictor XB look and that two, RA. to obtain And an first have the imaging early help serve and healthy our to a reproducibility study to at X, are sample mirroring tilmanocept of arms as treatment Phase and are evaluating upcoming the ability the
and arms the were As presented three have interim positive. all from discussed very past, results the in we
alpha get out look the a RA, that represent own about in subset rest in with tilmanocept high otherwise single and and imaging anti-TNF from who standard of In prediction subjects, baseline XX% without fibroid analysis the to tilmanocept value joints and efficacy was early can be able to ability could At therapy. from the therapy, combination anti-TNF of level a to ongoing seeing We on and alpha complete arm imaging avoiding be to a in that class initial the therapy non-responders possible provide for subtypes group reproducible involved use worsening therapy provide the scan that patients. accuracy that scan, of this demonstrate controls and with to patients, in to of from set possible the low of can disease predict anti-TNF case. RA scan continues its strong the on this alpha these effects uptake of non response robust likely anti-TNF RA high inflammation, particular in joints in to rheumatologists This alone to the rule clinical active baseline would with of time, those for of three technetium non-response are gold can particular time an a side be using demonstrating therapies XXM rate is tilmanocept to have patients predictive of In results defined the cost, we their quantitative patients entire alpha tool overall a continued an the healthy go, a in assessment. treatment and powerful patients their the data imaging very capacity data exhibiting define point predictive there good. the of even the
containing and three was doing and FDA doing plan the results They that that Overall, the we medical the RA treatment. Type that like interim the we During analysis are X. beginning this Phase meeting X that dataset, of proposing last from continue the remain it patient study, of are in continue how we to the full quarter, we design we address B and with feedback the submitted requested briefing it, once with package the They help They positive. agree X FDA. why are tilmanocept and done alignment. with constructive that we arms the a we communication. us the we occurs Xb tool end have Phase has the are the what provided well the analysis proposed as prior received as could complete to feedback understand And Phase doing, we of Phase predictive unmet have in imaging large typical is need our
like the Phase was data we in before overall at unexpected that it see the that arm set three the sample is they X. start small, the size to relatively look would interim not Given full
meeting so end we write when we up. will the for ask that and of analysis finish X Phase And
with the You complete this hard of and the we're should analysis prior process them. having get to and it back kind the to report Phase is meeting to FDA, the X, of and this know that working usual initiation
also always will to mention in in imaging the has I are readout along good possible want place is keep well, significant close is this the complete. ensure everything to this as product. the to have to making been we that for benefit as when automating goal progress approval in we program commercial that X with Phase and Our communication move the FDA
response. add this ability with use to this non-RA involved should us establishing of as treatment XB tilmanocept trial We We those a the control that have This is positive a Phase This joints an to with on what inflamed database. and joint now of accuracy, do discriminate to data joint enable the an like for both opened called is tilmanocept inflamed NAVX-XX to from have integral in our normal RA normative current looks ability predict and study should control as the normative joints start database size of of RA, well database will product. healthy study impact role to Phase our in set part X to a what of the normative up healthy joints knowledge like not discriminate from healthy have looks parameters the to from the the the one will inflammation the quantitatively. the we commercial to RA essential current arm parameters, what improved play analysis these use data establish
There of additional to healthy and for subjects I position purposes. these mentioned feasibility this involved of SPECT in on of be for some arm to utility number imaging, of in patients us of SPECT/CT a this are advantages order RA As possible an using call should a good potential put and the SPECT/CT and last trial the to this type evaluate in pilot looking imaging open establish objective will as will to application first ever growing We've first healthy the with for to well and volunteers opened SPECT/CT as already tilmanocept up in Phase imaging up up, This now as in of and good a RA. the others the several X, eight sites fact, shortly. run the site forward trial with the [start] would the number, study. an lined of number has biopsy by parallel
patients site a of up comparative approval in to patients now we’ve therapeutics. from its they're of RA that with maintains trials NAVX-XX, patients. have University And initial RA a study, pharma located we But for he this XB principal histopathology opening UK but these is this of with of the possible required Bard we the rounds is examination is obtain study, qualification selected and in it physician patients in going moment, in joints. of well The not comparing RA, for and engage FDA the in open use there. results a inflamed investigator into is as the to Phase the We as to this related leading delays screening where pathology imaging lead biomarker of from mentioned, critical biopsy reason believe Jed aim Health of biopsies. new are couple tilmanocept biopsy world's is indications were the trial of the from for, order of with their we for the that CDXXX COVID of recruit as in Northwestern we're RA subtypes imaging as and to speaking RA. joints site. achieve for both opened biopsies of the UK is tissues as RA with of actively in each London, for RA, to specializing There site our So lab this and pathological he the Remember, joint trial of three
also the biology fundamental We of standard a gold rheumatologists readout our to provide RA. imaging information with and related patient’s will
of tilmanocept could might this implications For management study a not therefore have what that on might determine could used subtype be on of the directly patients. would have class imaging results work RA demonstrate to therapies or can impact This and particular that for this example, immediate patient. of patient's from RA,
the And work are at imaging enrollment. atherosclerotic very investigator to front, disease they plaque study close Boston. cardiovascular the in full on MGH achieving On continues initiated
The and just been far plaque of localization our in continue fact, of of they we terms have in we to what also data XX to need them In volunteers. University a seen more are couple thus they've sites of study with promising for pilot with the studies of NIH-funded be Birmingham, tilmanocept of previously. tilmanocept reported ongoing. imaging Preclinical project line in Gallium we the Alabama, co-published with
front, therapeutic we strides On forward. the continue make to
to different For we have phenotype alone. are indications therapy. action and that doxorubicin models in We've drug we seen as rate order immunosuppressive compared to synergistic with to at performed proof and macrophage approved more pro a our concept state, our therapies. different effect change an preclinical tumour move excited with growth with significantly this reduced need inflammatory These by a the animal oncology, the an of important studies of molecule containing on in tumours approved results combined inhibitor that reduction in Put now models remember grow tumour demonstrate thus drug forward, using to mechanism combined are an in and approved well with construct studies simply, that as be the a from done far. checkpoint
begin preclinical more Frontiers our including schedule New studies, presenting We the York And different quarter. can will Further Cancer in looking our at be results therapeutic using so X:XX forward. at Symposium Academy and dosing robust site. at performing are be Sciences, payloads therapeutic find release also Immunotherapy you of for therapy, these to May on coming studies and months, XXth We're on press the Web in weeks looking starting details and in is at earlier our set this pipeline p.m. points in vitro a we'll and these moving different study,
whether drug safety. to areas molecule, localization. related as have compounds also a for for it’d results far with positive of off delivery reaching of could to to interest the preclinical This We efficacy continue a increasing collect radiopharmaceutical implications and versus or the to related labeled be target therapeutic
we therapeutic molecule as diagnostic applications performance as the think We of well. producing will in improve as significant generation next make continue well to that both strides our towards
for University have You at highlight today a seen a tremendous release our application to looking wanted think announcing San California Phase at that perform We press earlier an to that the investigators might of grant have tilmanocept and Diego received imaging holds agent. kidney NIH as this promise study everyone. X
for there applications LYMPHOSEEK. are studies or available, initiated or become we one number You another me those we know of other as should supporting that in as way results will are also tilmanocept appropriate. And investigator of in highlight a
have On the for of for viral the relates therapies front, other methods allowance viral by a for family. of of and the titled, caused the flavivirus diseases, to including infections. This dengue, a from compounds IP notice we received application diagnosis and USPTO patent possible variety yellow and fever treatment diseases
another We and are have involving chemical also on the filed to related another of finishing invention RA, methods new prediction synthesis. touches treatment response of in disclosure putting
completion As active rights therapeutic wanted well next needed of indications. current We Phase as the the for largely provide I and X molecules and are our and that other diagnostic database our the agents, normative we on open for both disease we of and to on into will Those therapeutic remain the highlights that IP indications. and gen on this Phase studies, protection we mentioned update. the quarter last to specifically diagnostic of previously, dataset, the touch continue of while some protections focused progress believe we strategy biopsy analysis RA to have support currently Xb and pipeline, as an and our just enrollment for to preparation full push the
want and academic to efforts of for keep their moving team As tireless Thank thank and you. our the hard collaborators work. things clinical always, all research I here for network trial of to sites their
call like over Jed? would Jed. Now to turn I to back the
